기업 정보 불러오는 중
Just reported
Q4 FY2026 results
From Cencora's results release of 2026년 11월 4일. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
US$88.35B
+5.5% y/y
+4.2% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$2.71
-31% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$906.8M
-19% q/q
Guided
—
No guide given
Company outlook
Full year 2027
- EPS, adjustedUS$19.40 – US$19.75First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Cencora is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Distribution
Graded A or B and worth $2B or more: A first, then the largest.
All 11 graded companies in its industry
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026년 10월 21일CBGraded C, now B
MCKMckesson Corporation2026년 11월 4일BAGraded B, now A
CVSCVS Health Corp2026년 11월 4일BAGraded B, now A
EWEdwards Lifesciences Corporation2026년 11월 4일BAGraded B, now A
BIIBBiogen Inc.2026년 10월 28일BAGraded B, now A
Cencora, Inc.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.
